X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in development for the treatment of transcriptionally addicted solid tumors.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
The analysis further showed that KB-0742 continues to demonstrate a differentiated pharmacokinetic (PK) profile, with oral bioavailability and dose-proportional exposure across all four dose levels, and low to moderate variability between patients.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) and is being developed for the treatment of MYC-amplified and transcriptionally addicted solid tumors and is currently being assessed as part of an ongoing Phase 1/2 study.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Preclinical data featured in three posters show potential of KB-0742, a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Data include results from preclinical studies of KB-0742, orally bioavailable inhibitor of cyclin-dependent kinase 9 (CDK9) in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in development for the treatment of MYC-amplified solid tumors.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
KB-0742 is a transcription regulatory network modulator discovered using the company’s proprietary high-throughput screening platform.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Results showed that KB-0742 inhibited tumor growth in a prostate xenograft model, as well as other cancers addicted to high levels of oncogenic transcription.
Lead Product(s): KB-0742
Therapeutic Area: Oncology Product Name: KB-0742
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
